Centra Medyczne Medyceusz Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Clinical research at Centra Medyczne Medyceusz Sp. z o.o. includes studies in cardiovascular medicine focused on atherosclerotic cardiovascular disease, heart failure, and elevated lipoprotein(a). These trials are designed to assess whether new therapies can better prevent major heart-related events and improve outcomes for people at higher cardiovascular risk.
- Testing new treatments to reduce cardiovascular death and heart failure events
- Evaluating approaches for people with elevated Lp(a) and related atherosclerotic disease
- Studying whether therapies can lower the risk of myocardial infarction, stroke, and urgent coronary procedures
The site in Lodz contributes to research aimed at improving prevention and treatment strategies for serious cardiovascular conditions.
Musculoskeletal and Neural Physiological Phenomena
This research area at Centra Medyczne Medyceusz includes clinical studies related to bone health and physiological effects of contraceptive use in adolescent and adult women. The work focuses on understanding whether different contraceptive options may influence bone mineral density over time.
- Assessing the impact of contraceptive methods on bone mineral density at the lumbar spine
- Comparing a new contraceptive option with non-hormonal methods
- Supporting safer choices for adolescent and adult women through clinical evaluation
These trials aim to generate practical evidence that may help clinicians better balance contraceptive effectiveness with longer-term skeletal health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 11 of 12 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centra Medyczne Medyceusz Sp. z o.o.
lock Showing 1 of 9 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21197) A multicenter, randomized, prospective double-blind, cross over Phase 3 study to evaluate the efficacy and safety of 0.04 mmol Gd/kg body weight of gadoquatrane for MRI in adults with known or suspected pathology of any body region (except CNS), compared to 0.1 mmol Gd/kg approved macrocyclic gadolinium-based contrast agents (GBCAs) | Bayer AG | Phase III | Not Recruiting | Sep 2023 | Dec 2024 |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Balcinrenone | 1 | Unknown | 2024-07-12 | 2024-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.